地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:18771149750
邮箱:sales@amyjet.com
<艾美捷科技代理AxisPharm品牌全系列产品
AxisPharm是一家专业的分析服务提供商,致力于为科学研究界和工业界提供高质量的分析服务。凭借先进的仪器设备和专业的技术团队,AxisPharm在生物分析、化学分析和质量控制领域树立了良好的声誉。AxisPharm公司的产品线包括:PEG 连接子、用于药物递送的脂质、荧光染料、单击化学试剂、聚聚乙二醇,共聚物、可裂解的连接子、抗体和抗体药物偶联物ADC、ADC 有效载荷、细胞生物学试剂、脱氧核糖核酸、修饰语、探针、合成肽、目标特定链接器、硫醇反应性接头、酸反应性连接子、胺反应性连接子、羰基反应性连接子、探针、修饰符。

▍AxisPharm产品线
● PEG连接子:聚合物聚乙二醇是多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 用于药物递送的脂质:在药物递送系统中起着至关重要的作用,特别是在脂质体、脂质纳米颗粒或脂质胶束等脂质制剂中。脂质提供结构稳定性,增强药物溶解度,实现控释,并促进靶向药物递送。
● 荧光染料:也称为荧光团或荧光探针,是吸收一种波长的光并以更高波长发射的化合物,从而产生可见荧光。它们是生物学研究中的重要工具,用于标记和检测蛋白质、核酸和细胞等生物分子,从而在显微镜、流式细胞术和实时荧光定量 PCR 等应用中实现灵敏和精确的可视化。
● 点击化学试剂:具有高特异性和最少的副产物,简化了复杂的合成过程。因此,它们在分子生物学、材料科学和药物化学中发挥着至关重要的作用。
● 聚合物聚乙二醇:多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 可裂解连接子:一类重要的分子,广泛应用于药物发现、化学生物学和材料科学等各个领域。这些连接子充当两个或多个分子实体之间的连接桥,可以在特定条件下选择性地裂解,从而释放附着的分子。这一特性使它们成为生物活性化合物靶向药物递送、成像和控释的有吸引力的工具。
● 抗体及抗体-药物偶联物及细胞生物学试剂:种类丰富可选择。
● ADC有效载荷:作为 ADC 的三个主要成分之一,有效载荷是高活性和有毒的药物分子,通过化学连接子附着在抗体上。有效载荷可以是小分子、蛋白质毒素、生物活性肽、酶,甚至放射性核素。通过适当的接头与适当的载体系统耦合的有效载荷可能会显示出靶向药物递送的特异性和有效性的提高。
● 脱氧核糖核酸:DNA 是脱氧核糖核酸的缩写,是一种包含所有生物体发育和功能的遗传指令的分子。DNA 由四个基本组成部分组成,称为核苷酸,由糖、磷酸基团和含氮碱基组成。
● 改性剂:改变其他分子或材料特性的化合物。在药物研发领域,改性剂在新型药物递送系统和生物医学设备的设计和优化中发挥着至关重要的作用。一种常见的改性剂类型是官能团,它是赋予分子特定化学和物理性质的原子的特定排列。
● 探针:AxisPharm 提供各种靶标特异性探针,例如叶酸 PEG、生物素 PEG、PROTAC PEG、荧光染料探针和图像探针。探针是一类含有官能团的化合物,旨在选择性地与生物分子(如酶、受体和核酸)相互作用。这些官能团包括荧光染料、生物素和亲和标签等,可以检测和定量复杂生物系统中的特定分子。
| Different Types of Polyethylene Glycol PEG Linkers in Stock | ||||
| Acid PEG | Diketone PEG | Non-PEG linker | PFP ester PEG | Sugar PEG β-Glucuronide Linker |
| Aldehyde PEG | DNP PEG | PEG-t-butyl ester | Phosphonate PEG | Sulfonic acid PEG |
| Alkyne PEG | DBCO PEG | PEG-X-PEG | Polymer PEG | TCO PEG |
| Amino PEG | DSPE PEG | Peptide Linkers | Propargyl PEG | Tetrazine PEG |
| Aminooxy PEG | Fluorescent PEG | Lipid PEG | PROTAC Linker | Homobifunctional PEG |
| Azide PEG | Fmoc PEG | M-PEG | Silane PEG | Bromo PEG |
| BCN-PEG | Folate PEG | Maleimide PEG | SPDP PEG | Tosylate PEG |
| Benzyl-PEG | Thiol PEG | MeNH-PEG | Branched PEG | Bis-Sulfone PEG |
| Biotin PEG | Hydrazide PEG | NHS ester PEG | HyNic PEG | DOTA Reagent DOTA PEG |
| Bis-PEG-acid | Hydroxy PEG | Boc-PEG | Bis-PEG-NHS | Iodo PEG |
| Bis-PEG-NHS | Cleavable Linkers | |||
| Lipids for Drug Delivery | ||||
| Biotinyl Cap PE | Dodecanyl PE | Other Lipid | Phosphatidylcholine | Phosphatidylethanolamine |
| Biotinyl PE | Glutaryl PE | PDP PE | Phosphoglycerol | Ptd Thioethanol |
| Caproylamine PE | Ionizable Lipid | PE MCC | Phosphoserine | Succinyl PE |
| Cationic Lipid | Lipid PEG | Cyanur PE | MPB PE | |
| Fluorescent Dye | ||||
| AF Dyes | Cyanine Dyes | MB Dyes | Rhodamine Dye | Rox (carboxy-X-rhodamine) Dye |
| APDye Fluors | DNP PEG | JOE | R6G | Peptide Labeling Reagents |
| Bodipy Probes | Fluorescein (FAM) | Pyrene Probes | TAMRA Dye | Classic Fluorescent Dyes |
| IR Fluors | Quenchers | Coumarin 343 | ||
| Click Chemistry Tools & Reagents | ||||
| Alkyne PEG | BCN-PEG | PTAD Linker | Tetrazine PEG | Click Chemistry Auxiliary Reagents |
| Azide PEG | DBCO PEG | TCO PEG | Methylcyclopropene Linkers | |
| Polymer PEG | ||||
| Acrylate | Biotin | Fmoc | Lipoamide | Silane |
| Active ester | Boc | Folate | Maleimide | Stearic acid |
| Aldehyde | Carboxylic acid | guanlian1010 | MW 2000 | TCO |
| Amine | Cholesterol | Hydrazide | MW 5000 | Thiol |
| Azide | DBCO | Hydroxyl | Polysarcosine | |
| Cleavable Linkers | ||||
| -S-S-Cleavable | PC Cleavable | Disulfide Linkers | Dde Cleavable Linkers | β-Glucuronide Linkers |
| Cleavable Peptide | diazo biotin probes | DTSSP crosslinker | Photocleavable Biotin | |
| Antibody and Antibody Drug Conjugate (ADC) | ||||
| Inotuzumab | Trastuzumab | Enfortumab | Labetuzumab govitecan | Mirvetuximab soravtansine (solution) |
| Vobramitamab | Disitamab | Mirzotamab | Loncastuximab tesirine | Trastuzumab deruxtecan (solution) |
| Polatuzumab | Ozuriftamab | Brentuximab | Trastuzumab deruxtecan | ADC Control Human IgG1-Deruxtecan (DAR 8) |
| Gemtuzumab | Inebilizumab | Datopotamab | Cofetuzumab pelidotin | Glembatumumab vedotin |
| Daratumumab (PBS) | Denintuzumab | Sacituzumab govitecan | Belantamab mafodotin | Trastuzumab duocarmazine |
| Praluzatamab | Naratuximab | Tisotumab | Enfortumab vedotin-ejfv | Trastuzumab emtansine (solution) |
| Lorvotuzumab | Rolinsatamab | Trastuzumab emtansine | Telisotuzumab vedotin | Enfortumab vedotin-ejfv (solution) |
| Izeltabart | Mipasetamab | Datopotamab deruxtecan | Gemtuzumab ozogamicin | Brentuximab vedotin (solution) |
| Lupartumab | Iladatuzumab | ORM-5029 | Cantuzumab ravtansine | Depatuxizumab mafodotin |
| Cantuzumab | Briobacept | Ifinatamab deruxtecan | Tusamitamab ravtansine | ADC Control Human IgG1-Deruxtecan (DAR 4) |
| Lonigutamab | Tamrintamab | Tisotumab vedotin | Zilovertamab vedotin | Depatuxizumab MMAE |
| Moxetumomab | Sacituzumab | Disitamab vedotin | Polatuzumab vedotin | ADC Control Human IgG1-vcMMAF |
| Azintuxizumab | Upifitamab | Belantamab | Pivekimab | Sacituzumab govitecan (solution) |
| Lifastuzumab | Glembatumumab | Patritumab deruxtecan | Farletuzumab ecteribulin | |
| Payloads and Linker modified Payloads | ||||
| Exatecan | Belotecan HCl | SGD-1882 | Dolastatin 10 | MC-Val-Cit-PAB-Doxorubicin |
| SN 38 | Gimatecan | MMAF | Calicheamicin | Gly3-Val-Cit-PAB-MMAE |
| Amrubicin | Taltobulin | Auristatin E | Eribulin Mesylate | SuO-Glu-Val-Cit-PAB-MMAE |
| Mitomycin C | Dxd | Chlorambucil | Soblidotin (Auristatin PE) | Fmoc-G-amino-CH2O acetyl-Exetecan |
| Deruxtecan analog | Lurtotecan | PF-06380101 | Deruxtecan analog 2 | DM1-MCC-PEG3-Biotin |
| sulfo-SPDB-DM4 | Exatecan mesylate | Auristatin F | Paclitaxel | GGFG-amino-CH2O-acetyl Exetecan |
| Rubitecan | MC-DM1 | MMAF-methyl ester | MC-MMD10 | Mal-PEG8-Val-Cit-PAB-MMAE |
| (4-NH2)-Exatecan | Irinotecan | Doxorubicin-SMCC | SPDB-DM4 | DBCO-PEG4-Val-Cit-PAB MMAF |
| Topotecan | PNU-159682 | MMAD | 10-Hydroxycamptothecin | Topotecan Hydrochloride |
| CL2A-SN38 | DM4 | 7-Ethylcamptothecin | ||
| Cell Biology Reagents | ||||
| Neuro-DiO, lipophilic tracer | VU (5-Vinyl-uridine) | CM-DiI, lipophilic tracer | LumiTracker ER Green | ER-Tracker Red (BODIPY TR Glibenclamide) |
| Annexin V-AF 647 conjugate | DAPI, blue fluorescent nucleic acid stain | Propidium Iodide | Deep-Red Fluorescent Nissl Stain | MitoCLox, mitochondrial lipid peroxidation probe |
| Annexin V-AF 488 conjugate | LumiTracker Mito Rhodamine 123 | LumiTracker Mito Green FM | RAPID DiI, lipophilic tracer | Laurdan (6-Dodecanoyl-2-dimethylaminonaphthalene) |
| Annexin V, His Tag | Thiazole Orange | SynaptoProbe® Red | LumiTracker ER Red | Linear Polyacrylamide for Nucleic Acid Precipitation |
| DiD, lipophilic tracer | RH 237, potentiometric probe | SynaptoProbe® Green | RAPID DiO, lipophilic tracer | Fluo-4 AM, green fluorescent calcium indicator |
| DiR, lipophilic tracer | Hoechst 33342, blue fluorescent nucleic acid stain | LumiTracker® Mito Red FM | DiI, lipophilic tracer | YODi-1, green fluorescent nucleic acid stain |
| DNA | ||||
| CPG solid supports | DNA Stains | Modified Triphosphates | phosphoramidite | |
| Probes | ||||
| Biotin PEG | Folate PEG | Image Probes | PROTAC Linker | |
| Amine reactive Linkers | ||||
| Acid PEG | Aldehyde PEG | Bromo PEG | Maleimide PEG | NHS ester PEG |
▍AxisPharm提供的服务
● 蛋白质组学服务:提供质谱分析、蛋白质鉴定和定量服务。专注于生物标志物分析,帮助客户在复杂的生物样本中发现和验证潜在的生物标志物。
● 代谢组学服务:利用先进的LC-MS/MS技术进行代谢物分析,提供通路洞察,帮助客户理解代谢途径和生物过程。
● 高级LC-MS/MS服务:用于PK分析和HPLC分离,确保高精度和高效率的研究结果,提供PK/PD研究,支持药物开发和临床前研究。
▍AxisPharm部分产品列表
| Cat# | Name | M.W. | Purity |
| AP15197 | Exatecan | 435.45 | ≥98% |
| AP15072 | SN 38 | 392.4 | ≥95% |
| AP15226 | Amrubicin | 483.47 | ≥98% |
| AP15664 | Mitomycin C | 334.3 | ≥98% |
| AP15203 | 10-Hydroxycamptothecin | 364.35 | ≥95% |
| AP15204 | 7-Ethylcamptothecin | 376.41 | ≥95% |
| AP15210 | Rubitecan | 393.35 | ≥95% |
| AP15211 | (4-NH2)-Exatecan | 403.43 | ≥95% |
| AP15206 | Topotecan | 421.5 | ≥95% |
| AP15207 | Topotecan Hydrochloride | 425.5 | ≥95% |
| AP15202 | Belotecan HCl | 433.5 | ≥95% |
| AP15208 | Gimatecan | 447.5 | ≥95% |
| AP15227 | Taltobulin | 473.65 | ≥99% |
| AP15201 | Dxd | 493.48 | ≥95% |
| AP15209 | Lurtotecan | 518.56 | ≥95% |
| AP15196 | Exatecan mesylate | 531.55 | ≥98% |
| AP15200 | Deruxtecan analog 2 | 579.58 | ≥95% |
| AP15205 | Irinotecan | 586.68 | ≥95% |
| AP15224 | PNU-159682 | 641.62 | ≥98.24% |
| AP15220 | Soblidotin (Auristatin PE) | 701.98 | ≥95% |
| AP15225 | SGD-1882 | 725.8 | ≥98% |
| AP15213 | MMAF | 732 | ≥95% |
| AP15216 | Auristatin E | 732 | ≥95% |
| AP15311 | Chlorambucil | 304.21 | ≥98 |
| AP15219 | PF-06380101 | 743.01 | ≥95% |
| AP15214 | Auristatin F | 746 | ≥95% |
| AP15215 | MMAF-methyl ester | 745.99 | ≥98% |
| AP15187 | Doxorubicin-SMCC | 762.8 | ≥98% |
| AP15217 | MMAD | 771.06 | ≥98% |

OZ Biosciences是一家法国的新兴生物技术公司,其成立宗旨是帮助药物公司研发和生产新型的药物导入系统。研究方向主要集中在生物活性材料导入活体组织新技术的研发,2005年该技术研发获得了突破性进展,已经申请了多项国际专利。
OZ Biosciences公司的创办者是分子导入系统的国际权威,在此领域享有极高的声望。研发目标是建立新一代的核酸、蛋白、多肽和其它生物分子的转染导入系统,为广大科研工作者服务。该公司与许多国际知名企业、大学和科研机构有合作往来。OZ Biosciences公司产品极具特色,主打产品是基于纳米技术和生物技术的基础上发展起来的磁转染试剂,相对常规商业化转染试剂,其转染效率更高。
Since 2003, OZ Biosciences creates, develops and produces innovative molecular delivery systems specialized in transfection and transduction tools, for the worldwide scientific community and pharmaceutical industry. OZ Biosciences is focused on delivery technologies of biomolecules such as DNA, RNA and protein for in vitro and in vivo applications.
These past years, the life sciences have gone through a technological revolution. The progress achieved in genomic, functional genomic and proteomic areas has created fabulous opportunities for better understanding of basic biological processes and for the development of the next generation of medicines.
OZ Biosciences公司主要产品线:
(1)Magnetofection™: a unique gene delivery method for in vitro and in vivo applications.
(2)Lipofection: proprietary biodegradable lipid-based transfection reagents.
(3)Transduction tools: for producing, concentrating, storing and enhancing virus efficiency.
(4)3D transfection: allowing nucleic acid delivery directly into 3D matrix.
(5)Protein delivery systems: including antibody & based on biodegradable lipid nanoparticles.
(6)Cell specific reagents: For specific cells such as neurons and stem cells.
(7)Vaccine Adjuvants: Standard & novel adjuvants for antigenic & genetic immunization
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Accurate Chemical & Scientific Corporation公司成立于1974年,标准化流程生产高质量多克隆和单克隆抗体。公司市场覆盖广泛客户群体和应用领域,未政府实验室、大学研究中心、制药实验室以及医院临床中心服务。
1974 saw the incorporation of Accurate Chemical & Scientific Corporation. Accurate pioneered and introduced standardized, highly characterized polyclonal and monoclonal antibodies. Since 1975, Accurate has specialized in products for basic and R&D research as well as routine laboratory work. Accurate's market covers a broad range of customers and applications, serving government labs, university research centers, pharmaceutical laboratories, as well as hospitals, clinical and industrial centers.
Accurate chemical公司的主要产品包括:
Antibodies and Antigens
Monoclonal antibodies
Polyclonal antibodies
Lab Equipment
Biocolor Assay Kits
Cell Separation Media
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Accurate Chemical"> Accurate Chemical
艾美捷科技代理rPeptide品牌全系列重组蛋白及多肽产品。
rPeptide公司提供高质量的肽、试剂、蛋白质、抗体等,专注于老年痴呆症和帕金森病的研究。rPeptide专有的平台载体技术能够在大肠杆菌中以可溶性肽/蛋白质的形式重组表达困难的肽/蛋白质。rPeptide还提供大量的β-淀粉样蛋白、taus、突触核蛋白、钙调素、定制产品等。
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
rPeptide产品详情请见艾美捷科技丁香通商城:
https://vicbio.biomart.cn/supply/c_282851.htm
<| Beta Amyloid 7E7 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-1101-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-1101-4 | 1.0mg |
| Beta Amyloid 7E7 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-1102-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-1102-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-2201-1 | 50ug |
| Beta Amyloid 6C2 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-2201-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-2202-1 | 50ug |
| Beta-Amyloid 6C2, 100ug and Beta Amyloid (1-42) NH4OH 0.5mg | BA-2202-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-2202-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-2202-4 | 1.0mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-02 | 1 x .25mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-1 | 1 x 0.5mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-2 | 1 x 1.0mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-02 | 1 x .25 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-1 | 1 x 0.5 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-2 | 1 x 1.0 mg |
| Beta-Amyloid (1-40), Mouse, Rat | A-1007-1 | 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-1 | 5 x 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-2 | 5 x 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-02 | 250 ug |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-2 | 1 mg |
| Beta-Amyloid (1-40, D23N) | A-1013-1 | 100 µg |
| Beta-Amyloid (1-40, D23N) | A-1013-2 | 1.0 mg |
| Beta-Amyloid (1-40, F4W) | A-1011-1 | 100 µg |
| Beta-Amyloid (1-11) | A-1051-1 | 1.0 mg |
| Beta-Amyloid (1-11) | A-1051-2 | 5.0 mg |
| Beta-Amyloid (1-16) | A-1052-1 | 1.0 mg |
| Beta-Amyloid (1-16) | A-1052-2 | 5.0 mg |
| Beta-Amyloid (1-28) | A-1053-1 | 0.5 mg |
| Beta-Amyloid (1-28) | A-1053-2 | 1.0 mg |
| Beta-Amyloid (1-38) | A-1078-1 | 0.5 mg |
| Beta-Amyloid (1-38) | A-1078-2 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-1 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-2 | 5.0 mg |
| Beta-Amyloid (11-40) | A-1061-2 | 1.0 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-01 | 0.1 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-1 | 0.5 mg |
| Beta-Amyloid (11-42) | A-1063-2 | 1.0 mg |
| Beta-Amyloid (12-28) | A-1056-1 | 0.5 mg |
| Beta-Amyloid (12-28) | A-1056-2 | 1.0 mg |
| Beta-Amyloid (17-40) | A-1057-1 | 0.5 mg |
| Beta-Amyloid (17-40) | A-1057-2 | 1.0 mg |
| Beta-Amyloid (17-42) | A-1058-1 | 0.5 mg |
| Beta-Amyloid (17-42) | A-1058-2 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-1 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-2 | 5.0 mg |
| Beta-Amyloid (25-35) | A-1060-1 | 1.0 mg |
| Beta-Amyloid (25-35) | A-1060-2 | 5.0 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-1 | 0.5 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-2 | 1.0 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-1 | 0.5 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-01 | 0.1 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-2 | 1.0 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-1 | 0.5 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-2 | 1.0 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-1 | 0.1 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-2 | 1.0 mg |
| 15N Beta-Amyloid (1-40), Rat, U. labeled | A-1131-1 | 0.5 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-1 | 0.1 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-2 | 1.0 mg |
| 15N Beta-Amyloid (1-43), Uniformly labeled | A-1107-1 | 1.0 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-1 | 0.1 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-2 | 0.5 mg |
| 15N Beta-Amyloid (11-40), Rat, U. label | A-1140-1 | 1.0 mg |
| 15N Beta-Amyloid (11-40), Uniformly labeled | A-1137-1 | 1.0 mg |
| 15N Beta-Amyloid (11-42), U. label | A-1120-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-01 | 0.1 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-42) | A-1117-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-2 | 1.0 mg |
| Biotin-LC-Beta-Amyloid (1-42) | A-1118-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-40) | A-1113-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-42) | A-1119-1 | 0.5 mg |
| Calmodulin, Porcine, Biotinylated | C-1002-1 | 100 µg |
| Calmodulin, Porcine, Fluorescein | C-1003-1 | 100 µg |
| Calmodulin, Porcine, Rhodamine | C-1004-1 | 100 µg |
| Calmodulin, Wheat (Triticum aestivum), Biotinylated | C-1008-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Fluorescein | C-1009-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Rhodamine | C-1010-1 | 50 µg |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-1 | 50ug |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-2 | 100ug |
| Tau Protein Ladder, of all 6 isoforms | T-1007-1 | 50 µl |
| Tau Protein Ladder, of all 6 isoforms | T-1007-2 | 100 µl |
| Tau Starter Kit | T-1170-1 | 50 µg |
| Tau Starter Kit | T-1170-2 | 100 µg |
| Tau-352, (0N3R) | T-1006-1 | 50 µg |
| Tau-352, (0N3R) | T-1006-2 | 100 µg |
| Tau-381, (1N3R) | T-1004-1 | 50 µg |
| Tau-381, (1N3R) | T-1004-2 | 100 µg |
| Tau-383, (0N4R) | T-1005-1 | 50 µg |
| Tau-383, (0N4R) | T-1005-2 | 100 µg |
| Tau-410, (2N3R) | T-1002-1 | 50 µg |
| Tau-410, (2N3R) | T-1002-2 | 100 µg |
| Tau-412, (1N4R) | T-1003-1 | 50 µg |
| Tau-412, (1N4R) | T-1003-2 | 100 µg |
| Tau-441, (2N4R) | T-1001-1 | 50 µg |
| Tau-441, (2N4R) | T-1001-2 | 100 µg |
| Tau-441, (2N4R), G272V mutant | T-1013-1 | 50 µg |
| Tau-441, (2N4R), P301L mutant | T-1014-1 | 50 µg |
| Tau-441, (2N4R), R406W mutant | T-1011-1 | 50 µg |
| Tau-441, (2N4R), V248L mutant | T-1015-1 | 50 µg |
| Tau-441, (2N4R), V337M mutant | T-1012-1 | 50 µg |
| Tubulin, Porcine | T-1201-1 | 1.0 mg |
| Latherin | L-1001-1 | 50ug |
| Latherin | L-1001-2 | 100ug |
| Latherin | L-1001-3 | 0.5mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-1 | 0.5 mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-2 | 1.0 mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-1 | .5mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-2 | 1.0mg |
| Alpha Synuclein Mouse | S-1010-1 | 0.5mg |
| Alpha Synuclein Mouse | S-1010-2 | 1.0mg |
| Alpha-Synuclein | S-1001-1 | 0.5 mg |
| Alpha-Synuclein | S-1001-2 | 1.0 mg |
| Alpha-Synuclein, 1-60 | S-1011-1 | 0.5 mg |
| Alpha-Synuclein, 1-95 | S-1012-1 | 0.5 mg |
| Alpha-Synuclein, 112 (NACP 112) | S-1016-1 | 0.5 mg |
| Alpha-Synuclein, 61-140 | S-1013-1 | 0.5 mg |
| Alpha-Synuclein, 96-140 | S-1014-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-2 | 1.0 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-1 | 0.5 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-2 | 1.0 mg |
| Alpha-Synuclein, A53T mutant | S-1002-1 | 0.5 mg |
| Alpha-Synuclein, A53T mutant | S-1002-2 | 1.0 mg |
| Alpha-Synuclein, Delta NAC | S-1015-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-2 | 1.0 mg |
| Beta-Synuclein | S-1003-1 | 0.5 mg |
| Beta-Synuclein | S-1003-2 | 1.0 mg |
| Gamma-Synuclein | S-1007-1 | 0.5 mg |
| Gamma-Synuclein | S-1007-2 | 1.0 mg |
| Gamma-Synuclein, Mouse | S-1009-1 | 0.5 mg |
| Gamma-Synuclein, Mouse | S-1009-2 | 1.0 mg |
| APP 669-711, HCl | AP-1156-1 | 0.5mg |
| APP 669-711, HCl | AP-1156-2 | 1.0mg |
| APP 669-711, HFIP | AP-1153-1 | 0.5mg |
| APP 669-711, HFIP | AP-1153-2 | 1.0mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-1 | 0.5mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-2 | 1.0mg |
| APP 669-711, NaOH | AP-1155-1 | 0.5mg |
| APP 669-711, NaOH | AP-1155-2 | 1.0mg |
| APP 669-711, NH4OH | AP-1157-1 | 0.5mg |
| APP 669-711, NH4OH | AP-1157-2 | 1.0mg |
| APP 669-711, TFA | AP-1001-1 | 0.5mg |
| APP 669-711, TFA | AP-1001-2 | 1.0mg |
| Apolipoprotein E, Human Plasma, VLDL | A-2001-1 | 50 µg |
| Alpha 1 Antichymotrypsin | A-2002-1 | 100 µg |
| Alpha 1 Antitrypsin | A-2003-1 | 1.0 mg |
| Alpha 2 Macroglobulin | A-2004-1 | 1.0 mg |
| Chymotrypsin | A-2005-1 | 100 µg |
| Haptoglobin | A-2006-1 | 1.0 mg |
| Myeloperoxidase | A-2007-1 | 100 µg |
| Plasmin | A-2008-1 | 1.0 mg |
| Plasminogen | A-2009-1 | 1.0 mg |
| Transferrin | A-2010-1 | 100 mg |
| Calmodulin, Porcine | C-1001-1 | 1 mg |
| Calmodulin, Wheat (Triticum aestivum) & Porcine | C-1006-1 | 200 µl |
| Calmodulin-SH, Wheat (Triticum aestivum) | C-1007-1 | 250 µg |
| Calmodulin-SH, Wheat (Triticum aestivum), Immobilized | C-1011-1 | 200 µl |
| Alpha Synuclein 10C3 Antibody | SA-3001-1 | 100ug |
| Alpha Synuclein 10C3 Antibody | SA-3001-2 | 1mg |
| Alpha Synuclein 10D2 Antibody | SA-3003-1 | 100ug |
| Alpha Synuclein 10D2 Antibody | SA-3003-2 | 1mg |
| Alpha Synuclein 5G4 Antibody | SA-3002-1 | 100ug |
| Alpha Synuclein 5G4 Antibody | SA-3002-2 | 1mg |
| Alpha Synuclein pAB 63 Antibody | SA-3004-1 | 100ul |
| Alpha Synuclein pAB 63 Antibody | SA-3004-2 | 1ml |
| Tau 3G3 | TA-3012-1 | 100ug |
| Tau 3G3 | TA-3012-2 | 1 mg |
| Tau 4C10 | TA-3011-1 | 100ug |
| Tau 4C10 | TA-3011-2 | 1mg |
| Tau 9D8 Antibody | TA-3010-1 | 100ug |
| Tau 9D8 Antibody | TA-3010-2 | 1mg |
| Tau total 12C2 | TA-3015-1 | 100ug |
| Tau total 12C2 | TA-3015-2 | 1mg |
| Tau total 18B5 | TA-3016-1 | 100ug |
| Tau total 18B5 | TA-3016-2 | 1 mg |
| Tau total 4B5 | TA-3013-1 | 100ug |
| Tau total 4B5 | TA-3013-2 | 1mg |
| Tau total 7E5 | TA-3017-1 | 100ug |
| Tau total 7E5 | TA-3017-2 | 1mg |
| Tau total 8F10 | TA-3014-1 | 100ug |
| Tau total 8F10 | TA-3014-2 | 1 mg |
| Tau total pAB 64 | TA-3020-1 | 100ul |
| Tau total pAB 64 | TA-3020-2 | 1 mg |
| Tau-10D3 Antibody | TA-3004-1 | 100ug |
| Tau-10D3 Antibody | TA-3004-2 | 1mg |
| Tau-10F8 Antibody | TA-3007-1 | 100ug |
| Tau-10F8 Antibody | TA-3007-2 | 1mg |
| Tau-1A6 Antibody | TA-2001-1 | 50ug |
| Tau-1A6 Antibody | TA-2001-2 | 100ug |
| Tau-1A6 Antibody | TA-2001-3 | 1.0mg |
| Tau-1A6 Antibody Kit | TA-1101-1 | 50ug |
| Tau-1A6 Antibody Kit | TA-1101-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-2 | 100ug |
| Tau-1E7 Antibody | TA-3001-1 | 100ug |
| Tau-1E7 Antibody | TA-3001-2 | 1mg |
| Tau-1F3 Antibody | TA-3005-1 | 100ug |
| Tau-1F3 Antibody | TA-3005-2 | 1mg |
| Tau-2B11 Antibody | TA-3008-1 | 100ug |
| Tau-2B11 Antibody | TA-3008-2 | 1mg |
| Tau-4G11 Antibody | TA-1001-1 | 50ug |
| Tau-4G11 Antibody | TA-1001-2 | 100ug |
| Tau-4G11 Antibody | TA-1001-3 | 1.0mg |
| Tau-4G11 Antibody Kit | TA-1111-1 | 50ug |
| Tau-4G11 Antibody Kit | TA-1111-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-2 | 100ug |
| Tau-5G7 Antibody | TA-3009-1 | 100ug |
| Tau-5G7 Antibody | TA-3009-2 | 1mg |
| Tau-8B11 Antibody | TA-3002-1 | 100ug |
| Tau-8B11 Antibody | TA-3002-2 | 1mg |
| Tau-8D2 Antibody | TA-3003-1 | 100ug |
| Tau-8D2 Antibody | TA-3003-2 | 1mg |
| Tau-9C8 Antibody | TA-3006-1 | 100ug |
| Tau-9C8 Antibody | TA-3006-2 | 1mg |
| Tau-E2+E3 9E11 | TA-3019-1 | 100ug |
| Tau-E2+E3 9E11 | TA-3019-2 | 1mg |
| Tau-E3 2B6 | TA-3018-1 | 100ug |
| Tau-E3 2B6 | TA-3018-2 | 1mg |
| AK-7 | N-3003-1 | 5 mg |
| AK-7 | N-3003-2 | 25 mg |
| ANA-12 | N-3031-1 | 5 mg |
| ANA-12 | N-3031-2 | 25 mg |
| Apomorphine HCI Hemihydrate | N-3027-1 | 100 mg |
| Apomorphine HCI Hemihydrate | N-3027-2 | 500 mg |
| Benztropine Mesylate | N-3012-1 | 1 gm |
| Bexarotene | N-3032-1 | 10 mg |
| Bexarotene | N-3032-2 | 50 mg |
| C-646 | N-3002-1 | 5 mg |
| C-646 | N-3002-2 | 25 mg |
| C16 | N-3030-1 | 5 mg |
| C16 | N-3030-2 | 25 mg |
| Candesartan | N-2049-1 | 20mg |
| Candesartan | N-2049-2 | 100mg |
| Celastrol | N-2187-1 | 10mg |
| Celastrol | N-2187-2 | 50mg |
| CNEE | N-1062-1 | 5mg |
| CNEE | N-1062-2 | 25mg |
| CTPB | N-3001-1 | 5 mg |
| CTPB | N-3001-2 | 25 mg |
| DAPT | N-3018-1 | 5 mg |
| DAPT | N-3018-2 | 25 mg |
| Deoxymannojirimycin HCl | N-2798-1 | 1mg |
| Deoxymannojirimycin HCl | N-2798-2 | 5mg |
| Diazoxide | N-3026-1 | 100 mg |
| Diazoxide | N-3026-2 | 500 mg |
| DMOG | MC-2371-1 | 10mg |
| DMOG | MC-2371-2 | 50mg |
| DU-14 | N-1187-1 | 5mg |
| DU-14 | N-1187-2 | 25mg |
| Edaravone | N-3034-1 | 1 gm |
| Edaravone | N-3034-2 | 5 gm |
| Entacapone | N-2025-1 | 10mg |
| Entacapone | N-2025-2 | 50mg |
| Epoxycholesterol | N-1330-1 | 1mg |
| Epoxycholesterol | N-1330-2 | 5mg |
| Ferrostatin-1 | N-1380-1 | 5mg |
| Ferrostatin-1 | N-1380-2 | 25mg |
| Fingolimod | N-3025-1 | 5 mg |
| Fingolimod | N-3025-2 | 25 mg |
| FK-506 | N-3024-1 | 20 mg |
| FK-506 | N-3024-2 | 100 mg |
| FPS-ZM1 | N-1635-1 | 5mg |
| FPS-ZM1 | N-1635-2 | 25mg |
| Gabapentin lactam | N-2535-1 | 50mg |
| Gabapentin lactam | N-2535-2 | 250mg |
| Imatinib Mesylate | N-3020-1 | 20 mg |
| Imatinib Mesylate | N-3020-2 | 100 mg |
| ISO-1 | N-3017-1 | 10 mg |
| ISO-1 | N-3017-2 | 50 mg |
| ISRIB | N-1539-1 | 5mg |
| ISRIB | N-1539-2 | 25mg |
| ISX9 | N-3010-1 | 5 mg |
| ISX9 | N-3010-2 | 25 mg |
| IU1 | N-1197-1 | 10mg |
| IU1 | N-1197-2 | 50mg |
| LM11A-31 2HCI | N-3005-1 | 5 mg |
| LM11A-31 2HCI | N-3005-2 | 25 mg |
| LM22A-4 | N-3006-1 | 10 mg |
| LM22A-4 | N-3006-2 | 50 mg |
| Minocyline HCI | N-3013-1 | 50 mg |
| Minocyline HCI | N-3013-2 | 250 mg |
| Mithramycin A | N-2085-1 | 1mg |
| Mithramycin A | N-2085-2 | 5mg |
| Mitoquinone | N-1363-1 | 5mg |
| Mitoquinone | N-1363-2 | 25mg |
| Montelukast Sodium | N-3028-1 | 50 mg |
| Montelukast Sodium | N-3028-2 | 250 mg |
| Mycophenolate mofetil | N-2086-1 | 50mg |
| Mycophenolate mofetil | N-2086-2 | 250mg |
| Neurodazine | N-3014-1 | 5 mg |
| Neurodazine | N-3014-2 | 25 mg |
| Neuropathiazol | N-3015-1 | 5 mg |
| Neuropathiazol | N-3015-2 | 25 mg |
| Noopept | N-2682-1 | 10mg |
| Noopept | N-2682-2 | 50mg |
| P7C3 | N-3004-1 | 5 mg |
| P7C3 | N-3004-2 | 25 mg |
| Phenylbutyrate Na | MC-1118-1 | 1gm |
| Phenylbutyrate Na | MC-1118-2 | 5gm |
| Pinacidil | N-2856-1 | 10mg |
| Pinacidil | N-2856-2 | 50mg |
| Prostratin | N-3011-1 | 1 mg |
| Prostratin | N-3011-2 | 5 mg |
| Rapamycin | N-3022-1 | 20 mg |
| Rapamycin | N-3022-2 | 100 mg |
| Resveratrol | N-3019-1 | 100 mg |
| Resveratrol | N-3019-2 | 500 mg |
| Roscovitine | N-1332-1 | 5mg |
| Roscovitine | N-1332-2 | 25mg |
| Salirasib | N-1461-1 | 5mg |
| Salirasib | N-1461-2 | 25mg |
| SB-225022 | N-3016-1 | 5 mg |
| SB-225022 | N-3016-2 | 25 mg |
| Tianeptine | N-3008-1 | 10 mg |
| Tianeptine | N-3008-2 | 50 mg |
| Tolcapone | N-3007-1 | 10 mg |
| Tolcapone | N-3007-2 | 50 mg |
| TRO 19622 | N-3029-1 | 5 mg |
| TRO 19622 | N-3029-2 | 25 mg |
| Vildagliptin | N-2887-1 | 20mg |
| Vildagliptin | N-2887-2 | 100mg |
| Vorinostat | N-3021-1 | 50 mg |
| Vorinostat | N-3021-2 | 250 mg |
| Zileuton | N-3023-1 | 10 mg |
| Zileuton | N-3023-2 | 50 mg |
| Zolmitriptan | N-3033-1 | 10 mg |
| Zolmitriptan | N-3033-2 | 50 mg |

艾美捷科技代理艾美捷科技代理Larodan品牌脂质产品。
Larodan公司设施位于瑞典斯德哥尔摩的卡罗林斯卡学院校园内。Larodan提供多种脂肪酸、甘油酸、磷脂及其他脂类相关物质。Larodan 生产高纯度脂质,用作标准品、试剂和原料,其化合物目录涵盖了大多数类别的脂质——从脂肪酸和氧脂素到甘油酯和磷脂。此外,Larodan公司还提供脂质和类脂化合物的定制合成服务。涉及生物科学研究、药物科学、食品油脂化学和营养科学等多个领域。产品范围主要包括:
(1)脂肪酸(Fatty Acids):提供多种饱和脂肪酸、单不饱和脂肪酸和多不饱和脂肪酸。
(2)氧脂素(Oxylipins):包括前列腺素、白三烯、羟基脂肪酸等氧化脂质。
(3)甘油酯(Glycerides):提供单酰基甘油、二酰基甘油和三酰基甘油(甘油三酯)。
(4)磷脂(Phospholipids):包括磷脂酰胆碱(PC)、磷脂酰乙醇胺(PE)、磷脂酰丝氨酸(PS)等。
(5)鞘脂(Sphingolipids):提供鞘氨醇、神经酰胺和鞘磷脂等。
(6)胆固醇及其衍生物(Cholesterol and Derivatives):提供胆固醇、胆固醇酯和氧化胆固醇等。
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Larodan品牌脂质产品"> 艾美捷科技代理Larodan品牌脂质产品

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

GlycoTech公司成立于1991年,是世界上最负盛名的糖生物学公司之一。Glycotech的使命是通过糖基团与它们受体之间的互相作用,发现和筛选出一系列具有药物潜力的化合物。GlycoTech还建立了世界上最大的稀有碳水化合物试剂库之一。
GlycoTech was founded in 1991 and remains today as one of the premier companies focusing on the biological functions and medical applications of glycoconjugates. The company has established its own research programs and has developed a large intellectual property portfolio. Through its catalog business, GlycoTech has also established one of the largest libraries of rare carbohydrate reagents and technologies worldwide.
GlycoTech的主要产品包括:
Cancer Diagnostics
Human Selectins
Carbohydrate Polymers
Carbohydrate Antibodies
HSA/BSA Conjugates
Cell Adhesion Apparatus
Human Endothelial Cells
Carbohydrates / Reagents
Carbohydrate Adsorbents
Research Protocols
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="GlycoTech"> GlycoTech
Glas Col的目标是成为一个在世界各地的实验室产品和工业加热和搅拌设备领域的领导者。大量实验室采用GLASCOL产品的加热套、定转子式均质器。
Glas Col加热套的优点:
1)外形贴合容器,节约空间;
2)质地柔软,可以避免局部过热;
3)最高温到400℃,能够满足大多数应用场景;
4)有观察孔,方面监测加热情况;
5)非常容易进行个性化定制。
Fabric Mantles:
·Fabric exterior provides effective heating in a space saving configuration
·Fabric interior to softly nest glass vessels and reduce the chance of thermal shock
·Withstands 400°C internal operating temperature, enough power for most applications
·Ideal for bottom holes, viewing ports, and other tubulations
·Easily customized for most applications
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Glas-Col"> Glas-Col
艾美捷科技代理Ludger品牌。
Ludger成立于1999年,位于英国牛津,是一家专注于糖科学(Glycoscience)和生物制药分析的公司,致力于为生物制药行业提供高质量的糖分析产品和服务。Ludger公司主要业务包括:
(1)糖分析产品:提供多种用于糖蛋白、糖脂和聚糖分析的标准品、试剂盒和仪器。
(2)分析服务:提供全面的糖分析服务,包括糖基化分析、糖结构鉴定和定量分析。
(3)定制化解决方案:根据客户需求,提供定制化的糖分析方案和研究服务。
Ludger公司产品线包括糖标准品、糖分析试剂盒、糖芯片、糖分析软件等;其采用先进的质谱技术、液相色谱技术和糖芯片技术,确保分析结果的高灵敏度和高准确性。Ludger公司产品应用范围包括:生物制药,涵盖单克隆抗体、融合蛋白、疫苗等生物制药产品的开发和质控;生物医学研究,支持糖生物学、糖免疫学、糖组学等研究领域;临床诊断,用于糖生物标志物的开发和临床应用,助力疾病早期诊断和个性化治疗。
<<<<<< " data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Ludger品牌"> 艾美捷科技代理Ludger品牌
Immunodiagnostik公司(德国)主要开发,生产和销售常规或科研用的体外诊断试剂和免疫化学产品。该公司专门研究临床实验诊断和医疗研究不同领域的创新免疫测定及其它分析方法(例如HPLC)。Immunodiagnostik的产品远销30多个国家,并与许多科研组织建立了合作关系,共同参与研究。公司通过和制药企业、学术界的协作,成功地开发出各种产品。
Immundiagnostik AG, founded in 1986, is a globally operating diagnostics company represented in over 70 countries. We focus on the development and production of innovative immunoassays and other analytical detection methods (e.g. HPLC and PCR) for medical routine and research. Furthermore, we offer a broad portfolio of antibodies and antigens.
Immundiagnostik offers a broad product and service portfolio in various clinical areas:
Cardiovascular and renal diseases
Skeletal system
Gastroenterology
Anti-Aging / Oxidative Stress
Immundiagnostik AG的主要产品包括:
Skeletal System
Fertility
Gastroenterology / Nutrition
Cardiovascular and Renal Systems
HPLC, LC-MS/MS
Clinical Immunology
Complementary Medicine
Molecular Biology
Oncology
Antigens
Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Immundiagnostik AG"> Immundiagnostik AG地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18995651644
传真:18327026838
邮箱:sales@amyjet.com
0.288